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Abstract
Background Septic cardiomyopathy worsens the prognosis of critically ill patients. Clinical data suggest that
interleukin-1β (IL-1β), activated by the NLRP3 inflammasome, compromises cardiac function. Whether or not deleting
Nlrp3would prevent cardiac atrophy and improve diastolic cardiac function in sepsis was unclear. Here, we investigated
the role of NLRP3/IL-1β in sepsis-induced cardiomyopathy and cardiac atrophy.
Methods Male Nlrp3 knockout (KO) and wild-type (WT) mice were exposed to polymicrobial sepsis by caecal ligation
and puncture (CLP) surgery (KO, n = 27; WT, n = 33) to induce septic cardiomyopathy. Sham-treated mice served as
controls (KO, n= 11; WT, n= 16). Heart weights and morphology, echocardiography and analyses of gene and protein
expression were used to evaluate septic cardiomyopathy and cardiac atrophy. IL-1β effects on primary and immortal-
ized cardiomyocytes were investigated by morphological and molecular analyses. IonOptix and real-time deformability
cytometry (RT-DC) analysis were used to investigate functional and mechanical effects of IL-1β on cardiomyocytes.
Results Heart morphology and echocardiography revealed preserved systolic (stroke volume: WT sham vs. WT CLP:
33.1 ± 7.2 μL vs. 24.6 ± 8.7 μL, P < 0.05; KO sham vs. KO CLP: 28.3 ± 8.1 μL vs. 29.9 ± 9.9 μL, n.s.; P < 0.05 vs. WT
CLP) and diastolic (peak E wave velocity: WT sham vs. WT CLP: 750 ± 132 vs. 522 ± 200 mm/s, P < 0.001; KO sham
vs. KO CLP: 709 ± 152 vs. 639 ± 165 mm/s, n.s.; P < 0.05 vs. WT CLP) cardiac function and attenuated cardiac (heart
weight–tibia length ratio: WT CLP vs. WT sham: 26.6%, P < 0.05; KO CLP vs. KO sham: 3.3%, n.s.; P < 0.05 vs. WT
CLP) and cardiomyocyte atrophy in KO mice during sepsis. IonOptix measurements showed that IL-1β decreased con-
tractility (cell shortening: IL-1β: 15.4 ± 2.3%, P < 0.001 vs. vehicle, IL-1RA: 6.1 ± 3.3%, P < 0.05 vs. IL-1β) and
relaxation of adult rat ventricular cardiomyocytes (time-to-50% relengthening: IL-1β: 2071 ± 225 ms, P < 0.001 vs.
vehicle, IL-1RA: 564 ± 247 ms, P < 0.001 vs. IL-1β), which was attenuated by an IL-1 receptor antagonist (IL-1RA).
RT-DC analysis indicated that IL-1β reduced cardiomyocyte size (P< 0.001) and deformation (P< 0.05). RNA sequenc-
ing showed that genes involved in NF-κB signalling, autophagy and lysosomal protein degradation were enriched in
hearts of septic WT but not in septic KO mice. Western blotting and qPCR disclosed that IL-1β activated NF-κB and
its target genes, caused atrophy and decreased myosin protein in myocytes, which was accompanied by an increased
autophagy gene expression. These effects were attenuated by IL-1RA.
Conclusions IL-1β causes atrophy, impairs contractility and relaxation and decreases deformation of cardiomyocytes.
Because NLRP3/IL-1β pathway inhibition attenuates cardiac atrophy and cardiomyopathy in sepsis, it could be useful to
prevent septic cardiomyopathy.
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Introduction
Sepsis is the leading cause of death of critically ill patients,
and septic cardiomyopathy contributes to this outcome.1 Car-
diomyopathy is found in half of septic patients.2 The problem
is underappreciated, possibly due to the observation that the
left ventricular ejection fraction (LVEF) in septic patients is
not invariably reduced from normal values and does not
reach the degree found in heart failure (HF). To assure an ad-
equate perfusion pressure during sepsis, a strong increase in
cardiac output is required. If this increase is insufficient to
meet metabolic needs, the diagnosis of septic cardiomyopa-
thy is established. The mortality of septic patients is directly
associated with systolic3 and diastolic4 cardiac dysfunction,
indicating that the prognosis of critically ill septic patients
rests on global cardiac dysfunction.5 Because cardiac function
normalizes within 2 weeks after sepsis, functional rather than
structural cardiac abnormalities have been implicated.6
Cardiodepressant inflammatory cytokines, particularly in-
terleukin-1β (IL-1β) and tumour necrosis factor (TNF), are sig-
nificantly increased during sepsis in both patients and animal
models.7 Importantly, an IL-1β antagonist attenuated the
haemodynamic and metabolic manifestations of septic
shock.8 IL-1β was reported to decrease myocardial contractil-
ity in vitro and ex vivo.9,10 IL-1β and TNF reduced cardiomyo-
cyte function in vitro, when cardiomyocytes were incubated
with serum from septic shock patients, and IL-1β
immunoabsorption diminished the cardiodepressant activity
of this serum.11 Nevertheless, structural abnormalities in
cardiomyocytes affecting sarcomeres, mitochondria and sar-
coplasmic reticula appear to be similarly important for septic
cardiomyopathy.12 IL-1β expression, maturation and secre-
tion are tightly controlled. Pro-IL-1β is the inactive IL-1β pre-
cursor; pro-IL-1β conversion to IL-1β and IL-1β-secretion are
mediated by inflammasomes. These multiprotein complexes
act as scaffolds for caspase-1-mediated maturation and se-
cretion of IL-1β and IL-18.13 Inflammasomes are involved in
sepsis and septic muscle failure.14 Cytoplasmic receptors of
the nucleotide-binding domain (NOD)-like receptor (NLR)
family are key inflammasome components.13 The NOD-, leu-
cine-rich repeat (LRR)- and pyrin domain-containing protein
3 (NLRP3) is one of the best characterized NLR proteins capa-
ble of forming an inflammasome complex. NLRP3 is
contained in the heart14–16 and skeletal muscle. Inflammation
in general and the NLRP3 inflammasome in particular are in-
volved in the pathophysiology of cardiovascular diseases,17
including HF18 and myocardial ischemia.19 All components
of the NLRP3 inflammasome are expressed in the heart albeit
at lower levels compared to tissues that are involved in
immune defence.20 However, myocardial NLRP3 and IL-1β
were shown to be upregulated in response to myocardial
ischemia.19 Recent studies have reported that inhibition
of the inflammasome may be useful to prevent ischemia-
induced myocardial damage.19 More specifically, inhibition
of the NLRP3 inflammasome significantly reduced the infarct
size and preserved cardiac function that accompany myocar-
dial ischemia.21 It has also been shown that Ca2+/Calmodu-
lin-dependent protein kinase II (CaMKII) δ-mediated
activation of the NLRP3 inflammasome in cardiomyocytes
mediates fibrosis and cardiac dysfunction in response to
chronic pressure overload.22 The NLRP3 inflammasome/
CaMKII pathway is also implicated in post-operative atrial
fibrillation in atrial myocytes from patients.23 These data
indicate that the NLRP3 inflammasome is involved in
inflammation-induced myocardial pathologies.
Consequently, several groups used Nlrp3 knockout (KO)
mice and/or NLRP3 inhibitors to investigate if the NLRP3
inflammasome is also involved in sepsis-induced HF.15,24–30
Interestingly, the NLRP3 inflammasome inhibitors melatonin
and cortistatin showed favourable effects in sepsis-induced
cardiac dysfunction in mice.26,27 Although an activation of
the NLRP3 inflammasome was reported to mediate cardiac
electrical and functional defects in low- and medium-grade
sepsis induced by the caecal ligation and puncture (CLP),25
this could not be found in high-grade polymicrobial sepsis
induced by the colon ascendens stent peritonitis (CASP)
model.24 Additionally, it is uncertain if deletion of the
NLRP3 inflammasome improves both systolic and diastolic
dysfunction in sepsis. Although echocardiography was
performed by some groups 8,15,25 1830 or 24 h24 after CLP
surgery, parameters of diastolic function were not reported
by all. In addition, not all groups performed echocardiogra-
phy to evaluate cardiac function in sepsis.25,27–29
Importantly in their work Kalbitz et al.15 showed a trend
towards a better diastolic function in Nlrp3 KO mice
compared with controls, which did not reach statistical
significance 8 h after CLP surgery.15 Finally, whether or not
deletion of Nlrp3 attenuates cardiac atrophy in sepsis has
not been investigated.
Because we have previously shown that IL-1β mediates
skeletal muscle atrophy in vivo and myocyte atrophy
in vitro,31 we hypothesized that this pro-inflammatory
cytokine also targets cardiomyocytes and the heart during
sepsis. We investigated if deletion of Nlrp3 inhibits
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sepsis-induced cardiac atrophy and if this is accompanied by
an improved diastolic and systolic cardiac function in
medium-grade sepsis after 24 h. To test if IL-1β is mechanis-
tically involved in septic cardiomyopathy, we performed a
novel high-throughput method called real-time deformability
assay to determine if IL-1β causes atrophy and affects the
mechanical properties of cardiomyocytes. We further
analysed if IL-1β via its receptor causes atrophy and
decreases relaxation and contractility of cardiomyocytes.
Finally, we performed next-generation sequencing of RNAs
isolated from the interventricular septum to identify path-
ways involved in septic cardiomyopathy.
Methods
Animal model of polymicrobial sepsis
All animal procedures were performed in accordance with
the guidelines of the Max Delbrück Center for Molecular
Medicine and the Charité-Universitätsmedizin Berlin and
were approved by the Landesamt für Gesundheit und
Soziales (LAGeSo, Berlin, Germany) for the use of laboratory
animals (permit number G 207/13). The investigation con-
forms to the Guide for the Care and Use of Laboratory
Animals published by the US National Institutes of Health
(NIH Publication No. 85-23, revised 1985), as well as the cur-
rent version of German law on the protection of animals.
Nlrp3 KO mice were kindly provided by Aubry Tardivel and
Nicolas Fasel of the University of Lausanne.32 Genotyping
was performed as recently described31 using primer pairs
shown in Table S1. CLP surgery was performed to induce
polymicrobial sepsis in 12- to 16-week-old male Nlrp3 KO or
Nlrp3 wild-type (WT) mice as recently described.31,33 Sham
mice were treated identically except for the ligation and
puncture of the caecum. Mice were sacrificed 96 h
after surgery.
Two-dimensional transthoracic echocardiography
Two-dimensional transthoracic echocardiography was per-
formed by two blinded technicians before and 24 h after
CLP or sham surgery and analysed by one blinded physician
(AH) as previously described.34 Briefly, mice were anaesthe-
tized with 2% isoflurane and kept warm on a heated
platform. Temperature and electrocardiography were contin-
uously monitored. Systolic and diastolic cardiac function and
morphology were assessed with a VisualSonics Vevo 2100
High-Resolution Imaging System with the use of a
high-resolution (38-MHz) transducer. Left ventricular (LV)
end-diastolic (LVIDd [mm]) and end-systolic dimension (LVIDs
[mm]), thickness of the left ventricular posterior wall in dias-
tole (LVPWthd [mm]) and systole (LVPWths [mm]), thickness
of the interventricular septum in diastole (IVSthd [mm]) and
systole (IVSths [mm]) and fractional shortening (FS, %) were
measured, and LVEF (%), cardiac output (CO [ml/min]) and
stroke volume (SV [μl]) were calculated. Peak mitral inflow
E (mm/s) and A (mm/s) velocity waves on pulsed-wave
Doppler were measured from the apical four-chamber view.
The ratio of peak flow velocity across the mitral annulus
during early and late diastole (E/A) was calculated from these
values as metric of diastolic dysfunction.
Isolation of adult ventricular rat cardiomyocytes
and measurement of cell shortening/relengthening
Isolation of ventricular cardiomyocytes from the hearts of
adult Wistar rats (adult rat ventricular cardiomyocytes
[ARVM]) was performed by retrograde collagenase perfusion
of the excised heart in a Langendorff apparatus as recently
described.35 Following incremental calcium restoration,
freshly isolated ARVM were suspended in buffer A (117 mM
NaCl, 2.8 mM KCl, 0.6 mM MgCl2, 1.2 mM KH2PO4, 1.2 mM
CaCl2, 20 mM glucose, 10 mM HEPES (2-[4-(2-hydroxyethyl)-
1-piperazinyl]-ethanesulfonic acid), pH 7.3), plated onto
laminin-coated wells (laminin from Engelbreth–Holm–Swarm
murine sarcoma basement membrane, Sigma-Aldrich) and
allowed to adhere for 1 h at room temperature. Only
rod-shaped cells that showed clear striations and no sponta-
neous contractions were used for further analysis. Mechani-
cal properties of cardiomyocytes were assessed using a
SoftEdgeMyoCam® system (IonOptix Corporation, Milton,
MA, USA) as described previously.35 After measurements of
basal contraction, ARVM were treated with vehicle (PBS),
IL-1β (10 ng/mL, Sigma-Aldrich) and an IL-1 receptor antago-
nist (IL-1RA) (10 μg/mL, Sigma-Aldrich; 30 min prior to IL-1β
treatment). Intracellular Ca2+ was measured and recorded
using a dual-excitation, single-emission photomultiplier sys-
tem (IonOptix) in ARVM loaded with the calcium fluorescent
probe Fura-2-AM (Sigma-Aldrich) and during field stimulation
of single ARVM (1 Hz, 5 ms). Changes in intracellular calcium
transients were inferred from the ratio of fluorescence inten-
sities excited at 340 and 380 nm. For calculation of changes in
systolic cell shortening and calcium transients, cell length and
Fura-2-AM fluorescence of the monitored cell were mea-
sured after a 2-min equilibrium period and again after
5 min. All data are shown as percentage change from base-
line. At least 10 different ARVM from at least six different
isolations were measured and used for calculations. The
IonOptix SoftEdge software was used to capture changes in
cell length during shortening and relengthening. Shortening
and relengthening of ARVM were assessed using the follow-
ing indices: cell shortening (the amplitude myocytes short-
ened upon electrical stimulation), indicative for peak ARVM
contractility; time-to-50% relengthening, the duration to
reach 50% relengthening, an indicative of diastolic duration
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(50% rather 100% relengthening was used to avoid noisy sig-
nal at baseline level); and change of relaxation speed, indica-
tive for the velocity of ARVM relaxation. The negative
inotropic activity (NIA) of IL-1β was defined as its ability to
decrease cell shortening more than the mean effect induced
by vehicle minus twice the standard deviation (mean  2×
SD).35 Because, vehicle (PBS) reduced the contractility of
ARVM by 3.98 ± 0.80%, we defined the threshold for NIA as
9.05% from baseline.
Real-time deformability cytometry
In the last decades, mechanical properties of cells have
been proven highly relevant to characterize cellular
function assumption-free without the need of antibodies
or fluorescent markers. Here, mechanical properties of cells
were measured by real-time deformability cytometry (RT-
DC) as described elsewhere36 using the AcCelerator
(Zellmechanik Dresden, Germany), a device that utilizes
a 30 × 30 μm cross-sectional constriction within a
microfluidic chip to measure the hydrodynamic deformation
of cells. Cell size and deformation were quantified using
high-speed image analysis of up to 1000 cells per second
in real time. Prior to the experiment, HL-1 cells were
treated with recombinant IL-1β (50 ng/mL) for 24 h. The
IL-1RA was added 30 min prior to IL-1β treatment. After
treatment, cells were washed with PBS and incubated with
Trypsin-EDTA (Sigma-Aldrich) for 1 min at room tempera-
ture. Detached cells were centrifuged at 500 × g for
5 min and resuspended in 0.6% (w/v) methylcellulose in
Mg2+- and Ca2+-free PBS. The prefilled microfluidic chip
was flushed with the cell suspension, and the flow was sta-
bilized at 0.16 μL/s for 1 min before measurements. For
each condition, more than 1000 mechanical single-cell mea-
surements were acquired. Material properties have been
extracted applying an analytical model that utilized the full
flow profile around a cardiomyocyte moving in the constric-
tion of the microfluidic system. Coupling the hydrodynamic
stress profile around the cell to linear elasticity theory and
solving the inverse problem enables decoupling of cell size
and deformation and calculation of a Young modulus. Data
analysis was carried out based on experimental triplicates
from three different days using linear mixed models.37
Briefly, by performing RT-DC on biological replicates each
consisting of several thousands of cells, the application of
linear mixed models allows for separation of random and
fixed effects in these large datasets. Fixed effects represent
the quantity of interest, whereas random effects summa-
rize all systematic and random measurement bias. Practi-
cally, two models are stated, one with and one without
the fixed-effect term, and statistical significance is calcu-
lated using Wilks’ theorem.
RNA sequencing and statistical analyses
For RNA sequencing, total RNA was isolated from the inter-
ventricular septum of three biological replicates (n = 3 mice
per group; i.e. Nlrp3WT sham, Nlrp3WT CLP, Nlrp3 KO sham,
Nlrp3 KO CLP) using TRIzol® Reagent (Invitrogen™, Life
Technologies Corporation, CA, USA) and the FastPrep-24™
instrument (MP Biomedicals GmbH) in accordance with man-
ufacturer’s instructions. RNAs were sequenced using the Ion
Torrent proton™ sequencing technology. In total, three se-
quencing runs were accomplished, each multiplexed with
one replicate of each sample type. The raw sequence data
in FASTQ-format are stored in the Sequence Read Archive
(SRA) at the National Center for Biotechnology Information
(NCBI) under the accession number SRP00123 (https://
www.ncbi.nlm.nih.gov/). The genes of interest that were dif-
ferentially expressed following CLP operation (using the con-
trast option of DESeq2 for CLP vs. sham) were chosen for
further analysis. Using the DAVID tool, the upregulated genes
as well as the downregulated genes were annotated using
the KEGG (Kyoto Encyclopedia of Genes and Genomes) data-
base to identify enriched categories, respectively. For the
most relevant enriched categories, heatmaps of their
assigned genes were generated. Those heatmaps provide
useful information about those genes of these categories that
were differently expressed in Nlrp3 WT and Nlrp3 KO mice.
Statistical tests
All experiments were performed independently and at least
three times using biological triplicates each. One-way ANOVA
with post hoc correction (Tukey’s post-comparison test) was
used to analyse all qPCR data from animal and cell culture
samples. Paired t-test was used to study the distribution of
myotube diameter in H9c2 myotubes. Differences were con-
sidered statistically significant at P ≤ 0.05. Data are shown
as mean ± standard error of the mean (SEM) or standard de-
viation (SD) as indicated in bar plots. The GraphPad Prism® 6
program (GraphPad Software, La Jolla, CA, USA), Adobe Illus-
trator CS6, Version 16.0.0, and Photoshop CS6, Version 13.0,
were used to perform statistics and draw graphics, respec-
tively. The data obtained from measurements of cell shorten-
ing are expressed as percentwise change from baseline, and
all values are given as mean ± SEM. Calculations were per-
formed with Stata 14.1 (StataCorp. LP, College Station,
USA), with a significance level of P ≤ 0.05. For statistical anal-
yses of RNA sequencing data, please refer to Methods.
Figures were drawn by Prism (Version 5). The documentation
of immunofluorescence and histological staining results were
performed with a Leica fluorescence microscope using
Leica cameras (DFC360 FX and DFC425) and the LAS.AF soft-
ware (version: 2.4.1 build 6384) and the LAS3.1 software
(Version 2.5.0.6735).
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For routine techniques, such as histological and immuno-
histochemical analyses, measurements of serum IL-1β, myo-
blast culture, differentiation and atrophy assay, RNA
isolation, cDNA synthesis and quantitative real-time-PCR,
protein extraction, Western blot assay and EMSA and more
information about RNA sequencing and statistical analyses,
please refer to Supporting Information.
Results
Nlrp3 deletion protects against septic
cardiomyopathy and reduces NF-κB signalling
We subjected Nlrp3 KO and Nlrp3WT mice to CLP (KO, n = 27;
WT, n = 33) and sham surgery (KO, n = 11; WT, n = 16). Com-
pared with WT mice, significantly less KO mice died after CLP
surgery after 96 h (57.6 vs. 29.6%; P < 0.05). Septic WT but
not KO mice showed a significant reduction in body, lung
and liver weights (Table S2). Heart weight-to-tibia length
(HW/TL) ratio (Figure 1A) was significantly decreased in
septic WT compared with sham mice (7.01 ± 1.23 vs.
5.15 ± 1.00 mg/mm; P < 0.02). In contrast, the HW/TL ratio
was not different between sham- and CLP-treated KO mice
(6.71 ± 0.65 vs. 6.49 ± 1.09 mg/mm; P = 0.53), indicating that
KO mice were protected from cardiac atrophy. Analyses of
haematoxylin–eosin and trichrome staining of histological
cross sections showed no interstitial fibrosis, irrespective of
genotype and treatment (Figure S1A–D). However, measure-
ments of myocyte cross-sectional area (MCSA) revealed that
myocytes of septic WT mice were significantly smaller when
compared with sham-treated WT mice. Although a reduction
in MCSA was also observed in septic KO compared with
sham-treated KO mice, this reduction was significantly
smaller when compared with MCSAs of septic WT mice
(Figure 1B).
Echocardiography (Figure 1C) showed a decreased LV
mass, stroke volume and cardiac output in WT CLP compared
with sham mice (Table S3). LVIDd and LVIDs were reduced in
WT CLP compared with sham mice. In contrast, LV mass,
stroke volume, cardiac output and LVIDd remained
unchanged in CLP compared with sham KO mice, whereas
LVIDs was also reduced in septic KO mice. Septic WT mice
showed a decrease in peak mitral inflow E and A and a re-
duced E/A ratio indicative for a decreased diastolic function.
These parameters remained unaltered in CLP KO mice. Our
data indicate that Nlrp3 deletion protects from cardiac atro-
phy and systolic and diastolic dysfunction during sepsis.
Because NLRP3 mediates the activation of IL-1β,13 we quan-
titated IL-1β serum levels in WT and KO mice. At baseline, IL-
1β serum levels were reduced in KO compared with WT mice
(Figure 1D). During sepsis, IL-1β serum levels increased in WT
mice, which was attenuated in KO mice (Figure 1D). In
contrast, cardiac Il1b expression in sepsis (Figure 1E) was inde-
pendent of the genotypes. Because IL-1β induces interleukin 6
(Il6) expression in myocytes,31 we investigated if decreased IL-
1β serum levels were accompanied with a decreased cardiac
Il6 expression in septic Nlrp3 mice. Indeed, cardiac Il6 expres-
sion increased in septic WT but not KO mice (Figure 1F). These
data indicate that Nlrp3 deletion leads to decreased IL-1β
serum levels and an attenuated expression of IL-1β-target
genes in the heart during sepsis.
In summary, our in vivo experiments revealed that de-
creased IL-1β serum levels were paralleled by an attenuation
of cardiac and cardiomyocyte atrophy and an improved dia-
stolic as well as systolic cardiac function in septic Nlrp3 KO
mice when compared with septic WT mice. To investigate if
these effects are mediated by IL-1β, we tested if it reduces
cardiomyocyte relaxation and contraction and mediates
cardiomyocyte atrophy in vitro.
IL1-β leads to a reduction in cardiomyocyte
contractility in vitro
We next performed IonOptix measurements to investigate if
IL-1β affects cardiomyocyte contractility and relaxation. IL-
1β caused a significant reduction in cardiomyocyte shorten-
ing and Ca2+-transients compared with vehicle (Figure 2A
and 2B). IL-1β also caused a significant increase in time-to-
50%-relengthening and a reduced relaxation speed compared
with vehicle (Figure 2C and 2D). An IL-1RA (Figure 2A–D) at-
tenuated those effects, indicating that IL-1β via its receptor
decreases both cardiomyocyte contraction and relaxation.
To characterize the effects of IL-1β on mechanical proper-
ties of cardiomyocytes, we performed RT-DC measurements
allowing single-cell analyses in a high-throughput fashion.
We subjected IL-1β and vehicle-treated HL-1 cardiomyocytes
to RT-DC and measured cell size and deformation. Compared
with vehicle-treated cells, IL-1β-treated cardiomyocytes were
significantly smaller (Figure 2E–G) and showed a significantly
reduced deformation (Figure 2E, 2F and 2H), but did not
differ in their mechanical properties (Figure 2I). These data
indicate that IL-1β-mediated atrophy is not compensated by
structural modifications, leading to a change in cardiomyo-
cyte stiffness.
RNA sequencing analyses, autophagy and
lysosomal protein degradation
To elucidate the mechanism involved in septic cardiomyopa-
thy and cardiac atrophy in vivo, we performed
next-generation sequencing of RNAs isolated from hearts of
CLP- and sham-treated WT and KO mice. Total raw reads,
mean read length, mapped reads and assigned reads for each
sample analysed are shown in Tables S4 and S5. Principal
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Figure 1 Nlrp3 KO mice show less cardiac atrophy and a preserved cardiac function during sepsis. 12- to 16-week-old male Nlrp3 KO and WT mice
were subjected to CLP or sham surgery. (A) Heart weight normalized to tibia length and expressed as percent-wise change compared with the respec-
tive sham group 96 h after CLP or sham surgery. CLP-treated Nlrp3 KO (n = 16); sham Nlrp3 KO (n = 8), CLP Nlrp3 WT (n = 12), sham Nlrp3WT (n = 13).
(B) Mean myocyte cross-sectional area (MCSA) determined in haematoxylin and eosin-stained histological cross sections from hearts of CLP-treated
Nlrp3 KO (n = 6), sham Nlrp3 KO (n = 6), CLP Nlrp3 WT (n = 6) and sham Nlrp3 WT (n = 6) mice (n = 100 myocytes per mouse). Data are presented
as mean ± SEM. *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001. (C) Results of transthoracic echocardiography of Nlrp3 WT sham (n = 13), Nlrp3 WT CLP (n =
13), Nlrp3 KO sham (n = 18) and Nlrp3 KO CLP (n = 18) mice 24 h after CLP or sham operation. (D) Serum IL-1β concentration in sham and CLP mice.
Nlrp3 WT sham (n = 15), CLP Nlrp3 WT (n = 12), Nlrp3 KO sham (n = 14), Nlrp3 KO CLP (n = 14). Data are presented as mean ± SEM. *P ≤ 0.05; **P ≤
0.01. qRT-PCR analysis of Il1b (E) and Il6 (F) expression in hearts of Nlrp3WT sham (n = 13), Nlrp3WT CLP (n = 12), Nlrp3 KO sham (n = 8) and Nlrp3 KO
CLP (n = 15) mice. mRNA expression was normalized to Gapdh. Data are presented as mean ± SEM. *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; n.s., not
significant.
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component analysis (PCA) (Figure 3A) indicated a good separa-
tion between normalized read counts of all experimental
groups. A homogeneous clustering and grouping were ob-
tained using hierarchical clustering on the same data
(Figure 3B). Comparison of the transcriptional profiles
revealed that sepsis resulted in an upregulation of 498 genes
in WT (Table S6) but only 103 genes in KO hearts (Table S7).
From the upregulated genes, only 21 genes were increased
in both septic WT and KO hearts (Table S8). Sepsis resulted
in a downregulation of 467 genes inWT (Table S9) but only five
Figure 2 IL-1β via the IL-1 receptor reduces contractility, relaxation and deformation of cardiomyocytes. (A–D) Adult rat ventricular cardiomyocytes
were treated with vehicle (PBS), recombinant IL-1β (10 ng/mL) or the IL-1 receptor antagonist (IL-1RA) (10 μg/mL), as indicated, and IonOptix measure-
ments were performed. Quantitation of effects on cell shortening (A) and Ca
2+
transients (B) are shown. The threshold is defined as a reduction of cell
shortening by 7.70% and is displayed by the red line. It equates to the mean effect on cell shortening induced by vehicle minus twice the standard
deviation of this effect. (C) Time-to-50% relengthening. (D) Change of relaxation speed. Values are expressed as mean percentage change from
baseline ± SEM. *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001. (E–I) Mechanical high-throughput characterization of HL-1 cardiomyocytes by RT-DC was used
to investigate the effects of IL-1β to cell size and deformation. (E) RT-DC scatter plots of cell size (area, μm2) and deformation of vehicle (PBS, control,
n = 2948 cells) and IL-1β (n = 2554 cells) treated HL-1 cells. Isoelasticity lines in grey highlight areas of equal elastic Young’s modulus. Colour code
indicates red (maximum) to blue (minimum) cell density. (F) Contour plot showing 50% (dashed) and 90% (solid) of maximum event density in vehicle
(black) and IL-1β (brown) treated HL-1 cells. Statistical analysis comparing cells size (median area; G), median deformation (H) and Young’s modulus (I)
of experimental triplicates from three different days using linear mixed models. Error bars represent SEM of the distribution. *P ≤ 0.05; ***P ≤ 0.001.
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Figure 3 Principal component analysis and hierarchical clustering of RNA sequencing data. (A) Principal component analysis (PCA) performed using
DESeq2 rlog-normalized RNA-seq data. Loadings for principal components 1 (PC1), PC2 and PC3 are shown in graph on x-, y- and z-axis. Genotypes
and treatments are indicated. (B) Hierarchical clustering analyses performed using DESeq2 rlog-normalized RNA-seq data. Colour code (from white
to dark blue) refers to the distance metric used for clustering (dark blue corresponds to the maximum of correlation values). Genotypes and treat-
ments are indicated. (C) Venn diagrams showing the number of twofold upregulated (top panel) and twofold downregulated (bottom panel) genes
and their overlap in hearts of septic Nlrp3 WT and Nlrp3 KO mice. (D) Selected enrichment scores of GO term analysis of genes, which were upregu-
lated (left panel) or downregulated (right panel) in hearts of septic Nlrp3 KO compared with Nlrp3 WT mice. (E) Heatmaps of normalized expression
values of genes involved in the NF-κB signalling pathway (left panel) and the autophagy and lysosomal pathway of protein degradation (right panel).
Genotypes and treatments as well as the z-score are indicated.
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genes in KO hearts (Table S10); those five genes were also de-
creased in hearts of septic WT mice (Table S11). These data in-
dicate that Nlrp3 deletion results in a blunted gene expression
response in the heart during sepsis. Upregulated as well as the
downregulated genes were annotated using the Kyoto Ency-
clopedia of Genes and Genomes (KEGG) database to identify
enriched categories. Pathways that are likely influenced by
DEG are shown as Table S12 (≥2-fold upregulated in WT CLP
vs. WT sham), Table S13 (≥2-fold downregulated in WT CLP
vs. WT sham) and Table S14 (≥2-fold upregulated in KO CLP
vs. KO sham). Due to the low number of downregulated genes
in hearts of KO CLP vs. KO sham mice, no KEGG pathway could
be identified. Importantly, genes upregulated in WT CLP- vs.
WT sham-treated mice belonged to the TNF signalling path-
way, NF-κB signalling pathway, insulin resistance, lysosome
and the TGF-ß signalling pathway (Table S12), which were all
not detected in hearts of KO CLP vs. KO sham mice
(Table S14). These data indicate that inflammation-related
pathways and pathways related to lysosome-associated pro-
tein degradation are induced in hearts of septic WT but not
KO mice. Gene Ontology (GO) term analysis revealed signifi-
cant enrichment of genes belonging to adhesion and develop-
mental processes in hearts of septic KO compared with WT
mice (Figure 3D, left). Genes involved in biological regulation,
metabolic and cellular process, developmental process and
immune system process were decreased in hearts of septic
KO when compared with WT mice (Figure 3D, right). Impor-
tantly, pronounced differences were found in the regulation
of genes involved in the GO term ‘immune system process’
(Figure S2). Further, genes involved in NF-κB signalling were in-
creased in hearts of septicWT but not KOmice (Figure 3E, left).
Among those 498 genes upregulated in hearts of septic WT
mice 19 genes belonged to the autophagy and lysosomal path-
way (ALP) of protein degradation (Figure 3E, right), whereas
only one of these genes (Rpl13a, ribosomal protein L13a)
was also increased in hearts of septic KO mice. In summary,
these data indicate that deletion of Nlrp3 is accompanied by
less pronounced changes in overall gene expression, a reduced
immune response, a reduction in NF-κB signalling and
increased ALP in the heart during sepsis.
To confirm changes in ALP gene expression, we performed
qPCR and Western blot analyses. We found an increase in
Sqstm1 (encoding p62) and Map 1LC3b (encoding LC3) ex-
pression in hearts of septic WT but not KO mice (Figure 4A).
P62 as well as LC3-II protein contents were increased in hearts
of septic WT but not KO mice (Figure 4B). We also found an
Figure 4 Sepsis-induced expression of autophagy genes is attenuated in hearts of Nlrp3 KO mice. (A) qRT-PCR analysis of Sqstm1, Map 1LC3b, Ctsl,
Atg13 and Bnip3 in hearts of Nlrp3 WT sham (n = 13), Nlrp3 WT CLP (n = 12), Nlrp3 KO sham (n = 8) and Nlrp3 KO CLP (n = 15) mice. mRNA expression
was normalized to Gapdh. (B) Western blot analysis with anti-p62 and anti-LC3B antibody. Actin was used as loading control. (C) qRT-PCR analysis of
Trim63 and Fbxo32 in hearts of Nlrp3 WT sham, Nlrp3 WT CLP, Nlrp3 KO sham and Nlrp3 KO CLP mice. mRNA expression was normalized to Gapdh.
Data are presented as mean ± SEM. *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001.
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increase in autophagy-related protein 13 (Atg13), cathepsin L
(Ctsl) and Bcl2 interacting protein 3 (Bnip3), expression in
hearts of septic WT but not KO mice (Figure 4A). Because
the ubiquitin–proteasome system is involved in muscle
atrophy and mediates the breakdown of structural proteins,
especially myosin heavy chain,38 we investigated the regula-
tion of its key factors Fbxo32/atrogin1 and Trim63/MuRF1
but did not find them to be regulated (Figure 4C). These data
indicate that NLRP3/IL-1β contributes to an increased cardiac
ALP gene expression in septic mice.
IL-1β-induced cardiomyocyte atrophy and
influenced autophagy genes in vitro
Because IL-1β activates NF-κB signalling in skeletal
myocytes31 and lymphocytes, and our RNA sequencing data
revealed an activated NF-κB pathway in septic WT but not
KO hearts, which was paralleled by a reduction in IL-1β serum
levels in septic KO mice, we investigated if IL-1β stimulates
the NF-κB pathway in cardiomyocytes. Western blot analysis
showed that IL-1β increased NF-κB p65 phosphorylation in
H9c2 cells (Figure 5A). Electrophoretic mobility shift assay
(EMSA) revealed that IL-1β caused an increased binding of ac-
tivated NF-κB p65 to NF-κB response elements (Figure 5B).
qRT-PCR analysis showed that IL-1β increased the expression
of its target genes Il6 and Nlrp3 in myocytes, which was at-
tenuated by IL-1RA and the IKKβ-directed NF-κB inhibitor
BMS-345541, respectively (Figure 5C). These data indicate
that IL-1β, via the IL-1 receptor, activated the NF-κB p65 path-
way, which increased the expression of IL-1β target genes in
cardiomyocytes.
To analyse if IL-1β causes myocyte atrophy, we treated
H9c2 myotubes with increasing amounts of IL-1β and vehicle
for 72 h and measured myotube diameters. IL-1β treatment
resulted in a dose-dependent decrease in myotube diameters
of 25%, 35% and 40%, respectively (Figure S3A–C). IL-1β
treatment led to a dose- and time-dependent decrease in my-
osin heavy chain (MyHC) protein content in H9c2 cells, which
is consistently observed in atrophy31,38 (Figures 5D and S3D).
IL-1RA (Figure 5E and 5F) and BMS-345541 (Figure 5E and 5F)
attenuated IL-1β-induced atrophy, indicating that the IL-1 re-
ceptor and the IKK/NF-κB pathway were involved in this
phenotype.
Based on our RNA sequencing data, we next hypothe-
sized that IL-1β increases ALP gene expression. Using qPCR,
we found that IL-1β treatment increased Sqstm1/p62, Map
1lc3b/LC3b and Ctsl expression in H9c2 myotubes, which
was attenuated by IL-1RA (Figure 5G). In contrast, IL-1β
treatment had no effect on Fbxo32/atrogin1 and Trim63/
MuRF1 expression (data not shown). These data indicate
that IL-1β-induced cardiomyocyte atrophy is likely mediated
by ALP-dependent protein degradation and that MuRF1 and
atrogin1 are possibly not involved in this process.
Discussion
Sepsis is a life-threatening organ dysfunction caused by a
dysregulated host response to an infection. It is frequently
accompanied by septic cardiomyopathy, which increases
mortality. During sepsis, the cardiodepressant and inflamma-
tory cytokine IL-1β rapidly increases.7 However, the role of IL-
1β in septic cardiomyopathy is not well understood. Here, we
present evidence that septic cardiomyopathy concerns both
systolic and diastolic function. We show that inhibition of
the NLRP3/IL-1β axis protects against systolic and diastolic
dysfunction in sepsis. We used Nlrp3-deficient mice to inves-
tigate if activation of IL-1β is involved in septic cardiomyopa-
thy. Nlrp3-deficient mice showed an improved systolic and
diastolic cardiac function and increased survival in sepsis.
Our results are in accordance with recently published work
showing that Nlrp3 deletion reduces mortality31 and
sepsis-induced end-organ damage, such as cardiomyopathy,15
acute lung injury and muscle failure.31 Pharmacological
inhibition of NLRP3 might therefore be beneficial in sepsis.
Indeed, positive effects were reported for the NLRP3 inhibi-
tors hemin, which protected against CLP-induced acute lung
injury in mice,39 and scutellarin40 and glyburide,41 which
improved survival of mice with bacterial sepsis. If such an
approach is applicable to critically ill human patients awaits
further investigation.
Because cardiac function often normalizes in human
patients after sepsis,6 functional rather than structural ab-
normalities are thought to cause septic cardiomyopathy.42
However, structural changes in the heart were also
reported.12 Here, we show that cardiac function and struc-
ture deteriorates during sepsis and that inhibition of
NLRP3/IL-1β improves both entities. Early clinical studies
identified IL-1β as a myocardial depressant factor that me-
diates HF in sepsis.11 Elevated IL-1β serum levels are found
in septic human patients and animal models.7,43 In Nlrp3-
deficient mice, we found reduced IL-1β serum levels, both
at baseline and after CLP, reflecting the canonical pathway
of proteolytic cleavage of pro-IL-1β to IL-1β by the NLRP3/
caspase 1 pathway.13 Nevertheless, residual IL-1β amounts
in serum of Nlrp3 KO mice implicate additional pathways
involved in IL-1β-activation. In fact, a non-canonical path-
way involving caspase 11 (in human caspase 4/5)44 and
an alternative pathway involving caspase 845 also activate
IL-1β and may account for residual IL-1β levels. Although
our data suggest that the NLRP3 pathway primarily
activates IL-1β in sepsis, further studies are needed to
elucidate the role of the non-canonical and alternative IL-
1β-activating pathway in sepsis. A recent study reported
that the complement system activates the cardiac NLRP3
inflammasome in CLP-induced sepsis mediating cardiomy-
opathy and Nlrp3 deletion was shown to be
cardioprotective,15 which is in line with our data. In
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Figure 5 The IL-1β signalling pathway is contained and active in H9c2 cardiomyocytes. (A) Seven days differentiated H9c2 myotubes were treated with
recombinant vehicle, IL-1β (50 ng/mL) and TNF (5 ng/mL), as indicated, for 25 min. Western blot analysis was performed with anti-phospho-NF-κB p65
and anti-NF-κB p65 antibody. GAPDH was used as loading control. (B) Differentiated H9c2 cells were treated with recombinant vehicle, IL-1β (50 ng/
mL) and TNF (5 ng/mL), as indicated, for 15 and 35 min, and NF-κB-DNA-response element complex formation was analysed by EMSA. (C) Differenti-
ated H9c2 cells were treated with recombinant IL-1β (50 ng/mL), vehicle, the IL-1 receptor antagonist (IL-1RA) (10 μg/mL) and the NF-κB inhibitor
BMS-345541 (25 μM), as indicated. qRT-PCR analysis of Il6 (left panel) and Nlrp3 (right panel) is shown. mRNA expression was normalized to Gapdh.
(D) Differentiated H9c2 cells were treated with solvent or increasing amounts of recombinant IL-1β (10, 20 and 50 ng/mL) for 72 h. Western blot anal-
ysis of isolated proteins with anti-myosin heavy chain (MyHC)-slow antibody is shown. GAPDH was used as loading control. (E) Frequency distribution
histograms of cell width of vehicle, IL-1β (50 ng/mL), IL-1RA (10 μg/mL) and BMS-345541 (25 μM)-treated myotubes, as indicated, are shown, n = 100
cells per condition. (F)Mean myotube width. (G) Differentiated H9c2 cells were treated with vehicle or recombinant IL-1β (50 ng/mL), as indicated, for
72 h. qRT-PCR analysis of Sqstm1, MapLC3b and Ctsl is shown. mRNA expression was normalized to Gapdh. Data are presented as mean ± SEM.
*P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001.
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addition to this study, we attribute the beneficial effects
seen in KO mice to effects of IL-1β on cardiomyocytes. This
is supported by previous work showing that IL-1β decreases
myocardial contractility in vitro and ex vivo9,10 possibly
explaining the preserved cardiac function seen in septic
Nlrp3 KO mice that have reduced IL-1β serum levels. Also,
depletion of IL-1β by immunoadsorption reduced the NIA
of serum from septic human patients on cardiomyocytes.11
Likewise, the haemodynamic and metabolic manifestations
of septic shock were attenuated by an IL-1β antagonist.8
We show that IL-1β, via the IL-1 receptor, negatively affects
contraction and relaxation of cardiomyocytes and reduces
Ca2+ transients. The latter agrees with previous reports
showing that IL-1β negatively affects Ca2+ signalling in
cardiomyocytes causing proarrhythmic effects.46 Therefore,
decreased IL-1β levels might have contributed to
cardioprotection in septic KO mice. Our data also implicate
that IL-1β contributes to diastolic cardiac dysfunction dur-
ing sepsis. First, IL-1β via its receptor prolonged cardiomyo-
cyte relaxation and reduced deformation. Second, diastolic
cardiac function was preserved in Nlrp3 KO mice during
sepsis. Overall, we show that IL-1β is involved in the
pathogenesis of systolic and diastolic dysfunction by
decreasing cardiomyocyte contractility and relaxation and
Figure 6 Proposed mechanism of septic cardiomyopathy. (Left panel) Sepsis, caused by polymicrobial infection leads to an activation of the NLRP3
inflammasome, resulting in increased conversion of inactive pro-IL-1ß in active IL-1ß, which acts on cardiomyocytes via the IL-1 receptor complex
(IL-1R1/IL-1RAcP). Binding of IL-1 to its receptor causes an activation of NF-κB, which leads to increased protein degradation by the autophagy–lyso-
somal pathway (ALP), a decrease in myosin heavy chain content (MyHC), a reduced deformability and a decreased cardiomyocyte contraction and re-
laxation. This in turn causes septic cardiomyopathy with cardiac atrophy, systolic and diastolic cardiac dysfunction and increased expression of pro-
inflammatory cytokines in the heart. (Right panel) In Nlrp3 knockout mice, sepsis can no longer activate the NLRP3 inflammasome, generation of
IL-1ß is much reduced, and activation of NF-κB as well as NF-κB signalling is attenuated, which maintains cardiomyocyte size, deformability, contraction
and relaxation. As a result, Nlrp3 knockout mice show a normal cardiac function in sepsis without cardiac atrophy and preserved expression of
pro-inflammatory cytokines. Inhibitors of the NLRP3 inflammasome (e.g. haemin, scutellarin, glyburide and MCC950), IL-1ß (anti-IL-1 antibody; anti-
IL-1 Ab), IL-1 receptor antagonist (IL-1 RA) and NF-κB (IKKβ-directed NF-κB inhibitor BMS-345541) that hold therapeutic potential are indicated.
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that inhibition of IL-1β could have beneficial effects in sep-
sis. Our data extend the findings of Kalbitz et al.,15 who
showed a trend towards a better diastolic function in Nlrp3
KO mice compared with controls, which did not reach
statistical significance 8 h after CLP surgery. Because we
performed echocardiography 24 h after surgery, we hypoth-
esize that this discrepancy is related to differences in
timing. It is also tempting to speculate that IL-1β-induced
cardiac atrophy facilitates diastolic cardiac function, which
in turn occurs at later time points during sepsis. However,
if IL-1β directly mediated cardiomyopathy and cardiac
atrophy in sepsis needs to be proven. To this end, we as-
sume that administration of IL-1β will reverse the
cardioprotective effects seen in septic Nlrp3 KO mice.
Whether or not decreased cardiac function in sepsis is a
consequence of structural changes is not well understood.
Here, we show that IL-1β via its receptor and NF-κB causes
cardiomyocyte atrophy, which was accompanied by a
reduced MyHC content, and that KO mice were protected
from sepsis-induced cardiac atrophy. This observation
coincided with an improved cardiac function in septic KO
mice indicative for a close structure–function relationship.
RT-DC measurements revealed an increased stiffness of
cardiomyocytes in response to IL-1β, further implicating that
IL-1β causes structural changes. Further, IL-1β-induced struc-
tural changes are manifested as cardiac and cardiomyocyte
atrophy with a decrease in contractile sarcomeric
proteins negatively affecting cardiac function. We hypothe-
size that the preserved cardiac function in septic KO mice
was related to both functional and structural effects of IL-
1β on the heart.
Recently, we showed that IL-1β causes muscle atrophy and
reported an increase in atrogin1/Fbxo32 and MuRF1/Trim63
expression in skeletal muscle of septic mice.31 However, both
genes remained unchanged in hearts of septic mice, and IL-1β
had no effect on their expression in cardiomyocytes. There-
fore, we hypothesize that ALP-dependent protein degrada-
tion may be involved in sepsis-induced cardiac atrophy.
Indeed, ALP genes were enriched in hearts of septic WT but
not KO mice, indicating that two distinct protein-degrading
pathways mediate heart and skeletal muscle atrophy in sep-
sis. We also found an increase in LC3-II and p62 proteins in
hearts of septic WT but not KO mice. In vitro experiments
showed that IL-1β via its receptor contributes to transcrip-
tional regulation of selected ALP genes, suggesting that it is
involved in sepsis-induced cardiac atrophy. Indeed, clinical
and preclinical studies indicate that sepsis and ALP are closely
related in multiple organs including the heart.47–49 However,
the role of ALP in sepsis-related end-organ damage is not well
understood. On one hand, ALP inhibition was shown to im-
prove cardiac function in lipopolysaccharide (LPS)-treated
mice, indicating that ALP is maladaptive,49 which is in line
with our data. On the other hand and in contrast to our data,
in vivo models using CLP-induced sepsis47 and in vitro models
using LPS-treated cardiomyocytes suggest that ALP activation
is cardioprotective. Therefore, further studies are needed to
elucidate the role of ALP in septic cardiomyopathy.
Previously, it was shown that an activated NLPR3
inflammasome in the heart mediates LPS-induced cardiac
dysfunction, inflammation, apoptosis and pyroptosis in vivo
and in vitro.16 Although the LPS and the CLP model are
not directly comparable, these data support cardioprotective
effects of NLRP3 inhibition. In addition, the NLRP3
inflammasome in cardiomyocytes was shown to be involved
in pressure overload-induced HF.22 Although this mecha-
nism might account for the cardioprotective effects seen
here, we did not investigate the role of NLRP3 in
cardiomyocytes, but focused on the effects of IL-1β. Finally,
the NLRP3 inflammasome also mediates the conversion of
pro-IL-18 to the cardioactive cytokine IL-18.13 IL-18 mediates
cardiac dysfunction in animal models of acute myocardial in-
farction and pressure overload, and its inhibition protects
against LPS-induced myocardial dysfunction. Although
reduced IL-18 levels might have contributed to the
cardioprotective effects observed here, this hypothesis
needs to be proven.
Conclusions
NLRP3-mediated IL-1β activation in sepsis plays a role in in
the pathogenesis of septic cardiomyopathy, leading to cardiac
atrophy and decreased systolic and diastolic cardiac function
(Figure 6). Polymicrobial sepsis leads to an activation of the
NLRP3 inflammasome resulting in increased conversion of in-
active pro-IL-1ß in active IL-1ß, which acts on cardiomyocytes
via the IL-1 receptor complex (IL-1R1/IL-1RAcP). IL-1 via its re-
ceptor activates NF-κB, which causes an increased protein
degradation by the ALP, a decrease in myosin heavy chain
content (MyHC), a reduced deformability and a decreased
cardiomyocyte contraction and relaxation. This in turn results
in septic cardiomyopathy with cardiac atrophy, systolic and
diastolic cardiac dysfunction and increased expression of
pro-inflammatory cytokines in the heart. In Nlrp3 knockout
mice, sepsis can no longer activate the NLRP3 inflammasome,
generation of IL-1ß is much reduced, and activation of NF-κB
as well as NF-κB signalling is attenuated, which maintains car-
diomyocyte size, deformability, contraction and relaxation. As
a result, Nlrp3 KO mice show a normal cardiac function in
sepsis without cardiac atrophy and preserved expression of
pro-inflammatory cytokines. Inhibitors of the NLRP3
inflammasome (e.g. haemin, scutellarin, glyburide and
MCC950), IL-1ß (anti-IL-1 antibody; anti-IL-1 Ab), IL-1 RA
and NF-κB (IKKβ-directed NF-κB inhibitor BMS-345541),
which are indicated, could be useful to prevent septic
cardiomyopathy.
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Limitations
Sepsis in humans is a clinical problem that frequently occurs
at the extremes of ages, especially in elderly patients. For
our experiments, we have used 12- to 16-week-old mice,
which relates to a young age in human patients. A compara-
ble age range has also been used by other groups that
investigated the role of the NLRP3 inflammasome in septic
cardiomyopathy.15,24,25,28,29 Although the currently available
data on the role of NLRP3 on septic cardiomyopathy are
informative for a younger age, further studies on mature
(12-month-old) and aged mice (24-month-old) are needed
to provide data that are more translatable to aged patients
with sepsis.
All animal experiments shown here have been performed
in male mice. A gender imbalance is also apparent in work
published by other groups that only investigated male
mice,15,24,25 male rats27,30 or female mice.28,29 Because we
cannot extrapolate our findings to female mice or even
compare the effects between male and female mice, further
sex-specific studies are needed.
Given the role of the NLRP3 inflammasome in the
heart,15,22,26,50 it is tempting to speculate that its deletion
in cardiomyocytes contributed to the attenuation of septic
cardiomyopathy observed in Nlrp3 KO mice. However, this
question cannot be answered by our work. Based on our
data, we hypothesize that reduced IL-1β serum levels account
for diminished cardiac atrophy and the improved cardiac
function in septic Nlrp3 KO mice. Further studies are needed
to elucidate the contribution of the NLRP3 inflammasome
contained in cardiomyocytes for the pathogenesis of septic
cardiomyopathy, such as using cardiomyocyte-specific Nlrp3
KO mice.
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Figure S1. Nlrp3 KO mice are protected from septic cardio-
myopathy. 12–16-week-old male Nlrp3 KO and WT mice
were subjected to CLP or sham surgery. Haematoxylin and eo-
sin (A, B) and trichrome (C, D) staining of histological sections
from hearts of sham and CLP operated WT and Nlrp3 KO mice
at 96 hours after surgery, as indicated, are shown. Gross mor-
phology (A, C; Scale bar = 1 mm) and higher magnifications
(B, D; Scale bar = 100 μm) are shown
Figure S2. Genes involved in “Immune System Process” are
less activated in hearts of septic Nlrp3 KO mice. Heatmap
of normalized expression values of genes involved in Immune
System Process. Genotypes and treatments as well as the
z-score are indicated
Figure S3. IL-1β causes atrophy of cardiomyocytes in a dose-
and time-dependent manner. Differentiated H9c2 myotubes
were treated with increasing amounts of recombinant IL-1β
(10 ng/ml, 20 ng/ml, 50 ng/ml) or vehicle for 72 hours. A,
Representative light microscopy pictures. Scale bar = 250
μm. B, Frequency distribution histograms of cell width of ve-
hicle and IL-1β (10 ng/ml, 20 ng/ml and 50 ng/ml) treated
myotubes, n = 100 cells per condition. C, Mean myotube
width. D, Differentiated H9c2 myotubes were treated with
recombinant IL-1β (50 ng/ml) or vehicle for 3 hours, 6 hours,
12 hours, 24 hours, 48 hours and 72 hours, respectively.
Western blot analysis of isolated proteins using anti-MyHC
slow is shown. GAPDH was used as loading control. Data
are presented as mean ± SEM. **p ≤ 0.01, ***p ≤ 0.001,
****p ≤ 0.0001
Table S1. Primer pairs for genotyping of Nlrp3 KO and Nlrp3
WT mice
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Table S2. Body and organ weights 96 hours after CLP or
sham surgery
Table S3. Data of transthoracic echocardiography
Table S4. Total raw reads, mean read length, mapped reads
for each sample analysed
Table S5. Successfully assigned reads for each sample
analysed
Table S6. ≥ 2-fold upregulated genes in hearts of CLP vs.
sham treated Nlrp3 WT mice (.xls table; Table S5_wt_CLP vs
wt_sham_FC2.xlsx)
Table S7. ≥ 2-fold upregulated genes in hearts of CLP vs.
sham treated Nlrp3 KO mice (.xls table; Table S6_ko_CLP vs
ko_sham_FC2.xlsx)
Table S8. Twentyone genes upregulated in both septic Nlrp3
WT and septic Nlrp3 KO hearts compared to the respective
sham group
Table S9. ≥ 2-fold downregulated genes in hearts of CLP vs.
sham treated Nlrp3 WT mice (.xls table; Table S8_wt_CLP vs
wt_sham_FC-2.xlsx)
Table S10. ≥ 2-fold downregulated genes in hearts of CLP vs.
sham treated Nlrp3 KO mice (.xls table; Table S9_ko_CLP vs
ko_sham_FC-2.xlsx)
Table S11. Five genes downregulated in both septic Nlrp3 WT
and septic Nlrp3 KO hearts compared to the respective sham
group
Table S12. KEGG pathway analysis of significantly upregu-
lated genes in septic Nlrp3 WT compared to sham treated
Nlrp3 WT hearts
Table S13. KEGG pathway analysis of significantly downreg-
ulated genes in septic Nlrp3 WT compared to sham treated
Nlrp3 WT hearts
Table S14. KEGG pathway analysis of significantly upregu-
lated genes in septic Nlrp3 KO compared to sham treated
Nlrp3 KO hearts
Table S15. Primer pairs for quantitative real-time-PCR are
shown
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